Publications by Michael Batey - ePrints

Browsing publications by Michael Batey.

Newcastle Authors	Title	Year
Dr Britta Vormoor Henrike Knizia Michael Batey Dr Ian Wilson Dr Petra Dildey et al.	Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging	2014
Michael Batey Dr Frida Ponthan Dr Helen Blair Professor Olaf Heidenreich	The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy	2014
Michael Batey Dr Yan Zhao Suzanne Kyle Professor Herbie Newell Professor Nicola Curtin et al.	Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer	2013
Michael Batey Dr Frida Ponthan Professor Olaf Heidenreich	The use of a novel in vivo orthotopic imaging model of AML for assessment of drug efficacy	2013
Dr Joanne Martin Michael Batey Dr Yan Zhao Dr Celine Cano Dr Michele Tavecchio et al.	Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K	2012
Michael Batey Dr Yan Zhao Dr Helen Maitland Professor Hing Leung Dr Andrew Hall et al.	Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma	2011
Michael Batey Professor Julie Irving Professor Herbie Newell	Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models	2011
Patricia Garrido Castro Dr Simon Bomken Elda Latif Michael Batey Hesta McNeill et al.	ANGIOPOIETIN1 a Novel Factor Implicated In MLL Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene Dependent Manner	2010
Elda Latif Michael Batey Hesta McNeill Professor Hermann Josef Vormoor Professor Olaf Heidenreich et al.	ANGIOPOIETIN1-a Novel Factor Implicated In MLL-Rearranged Acute Lymphoblastic Leukemia and Regulated In a Fusion Gene-Dependent Manner	2010
Henrike Knizia Michael Batey Gilberto de Almeida Dr Ross Maxwell Dr Petra Dildey et al.	Development of an orthotopic model for human malignant bone diseases in immunocompromised NOD.Cg-Prkdc^scidIl2rg^tmlwjl/szj (NSG) mice	2010
Michael Batey Professor Herbie Newell Professor Nicola Curtin	Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]	2008
Michael Batey Dr Amy Peasland Professor Julie Irving Professor Herbie Newell	Development of inhibitors of the fibroblast growth factor receptor (FGFR) kinase using a fragment based approach	2008
Michael Batey Dr Helen Maitland Professor Hing Leung Dr Andrew Hall Professor Graham Jackson et al.	In vitro activity of the multi targeted receptor tyrosine kinase inhibitor sunitinib against multiple myeloma cell lines is not predictive of in vivo xenograft response	2008
Michael Batey Dr Laurent Rigoreau Professor Roger Griffin Professor Herbie Newell Professor Nicola Curtin et al.	Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract]	2008
Dr Patricia Turner Mike Cole Michael Batey Sandra Beare Professor Alan Boddy et al.	Reduced folate carrier single nucleotide polymorphism associated with methotrexate clearance in breast cancer patients	2008
Huw Thomas Dr Christopher Calabrese Michael Batey Suzanne Kyle Professor Herbie Newell et al.	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial	2007
Dr Yan Zhao Huw Thomas Michael Batey Dr Ian Cowell Professor Roger Griffin et al.	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441	2006
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Dr Christopher Calabrese Professor Nicola Curtin Michael Batey Huw Thomas Suzanne Kyle et al.	Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase	2000
Michael Batey Kevin Fishwick Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert et al.	Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer	1999
Dr Christopher Calabrese Huw Thomas Michael Batey Professor Nicola Curtin Professor Roger Griffin et al.	Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase	1999